US Gene Editing Market

US Gene editing Market Research Report Information By Technology (CRISPR, TALEN, ZFN, Antisense, and others), Application (Genetic Engineering, Gene Therapy, Cell Line Engineering, and Others), End User (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), and Academic & Government Research Institutes ) and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032.

ID: MRFR/LS/11815-US | 100 Pages | Author: MRFR Research Team | December 2023         

Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

North America is poised to dominate the global gene editing market, with several factors contributing to its prominent position. The region's robust market share is driven by a surge in the prevalence of cancer and genetic disorders, a growing inclination toward personalized medicine, increased funding from both the private and public sectors, and rapid advancements in sequencing and gene editing technologies.
In March 2021, a significant development took place as scientists from the University of California (UC) campuses in San Francisco, Berkeley, and Los Angeles gained approval from the Food and Drug Administration (FDA) to collaboratively initiate an early-phase clinical trial for a gene correction therapy in sickle cell disease patients. This groundbreaking trial involves utilizing the patient's blood-forming stem cells. Another noteworthy initiative is the National Institutes of Health (NIH) Somatic Cell Gene Editing (SCGE) Programme, which, as of June 2022, has allocated 24 new funds to researchers in both the United States and Canada. Over the next four years, the SCGE Programme is set to distribute a total of USD 89 million in advanced gene editing grants. This program, with a cumulative funding of around USD 190 million spread over six years, supports 45 initiatives, significantly contributing to the region's sustained market growth.

Moreover, a research study published in April 2022, titled "Transcription activator-like effector nuclease (TALEN) as a promising diagnostic approach for COVID-19," underscores the versatility and promise of TALEN. This gene editing tool offers advantages such as a broad range of target sites and high specificity, showcasing notable results compared to alternative approaches. TALEN proves crucial in diagnostic work-up and therapeutic challenges for infectious diseases, acting as an essential asset for the region's gene editing endeavors. The highlighted qualities of TALEN, including the potential for quick, on-site, and cost-effective diagnostic work-ups, particularly during pandemics, add to the momentum of market growth in the region.

The convergence of these factors, from groundbreaking clinical trials to substantial funding initiatives and the adaptability of innovative gene editing tools, positions North America as a key player in the global gene editing landscape. As the region continues to witness advancements in research, technology, and application areas, it is expected to maintain its leadership position, fostering a conducive environment for the growth of the gene editing market throughout the forecasted period.